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Mild hypothermia provides Treg 
stability
Marek- Trzonkowska Natalia1, Piekarska Karolina1, Filipowicz Natalia2,  
Piotrowski Arkadiusz2, Gucwa Magdalena2, Vogt Katrin3, Sawitzki Birgit3, Siebert Janusz4 & 
Trzonkowski Piotr5
Regulatory T cells (Tregs) play crucial role in maintenance of peripheral tolerance. Recent clinical trials 
confirmed safety and efficacy of Treg treatment of deleterious immune responses. However, Tregs lose 
their characteristic phenotype and suppressive potential during expansion ex vivo. Therefore, multiple 
research teams have been studding Treg biology in aim to improve their stability in vitro. In the current 
paper, we demonstrate that mild hypothermia of 33 °C induces robust proliferation of Tregs, preserves 
expression of FoxP3, CD25 and Helios, and prevents TSDR methylation during culture in vitro. Tregs 
expanded at 33 °C have stronger immunosuppressive potential and remarkably anti-inflammatory 
phenotype demonstrated by the whole transcriptome sequencing. These observations shed new light 
on impact of temperature on regulation of immune response. We show that just a simple change in 
temperature can preserve Treg stability, function and accelerate their proliferation, responding to 
unanswered question- how to preserve Treg stability in vitro.
Thymus derived, natural regulatory T cells (Tregs) constitute ≈1% of lymphocytes in peripheral blood, but they 
play a crucial role in maintenance of peripheral tolerance1,2. Lack of functional Tregs leads to onset of multiple 
autoimmune diseases and hypersensitivity as it is observed in immune dysregulation, polyendocrinopathy, enth-
eropathy, X-linked syndrome (IPEX)3. Tregs can be called “intelligent steroids” as physiologically their immu-
nosuppressive activity is targeted against pathological responses (e.g. autoimmunity, excessive inflammation, 
hypersensitivity) and do not impair immunity to infectious agents. Results of clinical trials, including our studies, 
confirmed that Tregs are safe therapeutic tool for treatment of deleterious immune responses4–10.
Our team has been working on biology and clinical application of Tregs for more than 10 years. We were the 
first group who administered ex vivo expanded Tregs in human in graft versus host disease (GVHD)4, in type 
1 diabetes (DM1)5–7 and recently in multiple sclerosis11. Currently, multiple different research teams have been 
tested ex vivo expanded Tregs in prevention and therapy of GVHD, DM1, and tolerance induction in kidney and 
liver transplantation (numbers of clinical trials listed in the ref.11). Thus, during the last 5 years a dynamic sprout 
of Treg based therapies has been observed.
In general, all Treg trials have the common goal- to provide an intelligent therapy that will inhibit deleteri-
ous immune reactions with no impact on physiological immunity. However, at the same time research groups 
conducting these studies struggle with the same technical problems that are: variable Treg proliferation rate and 
continuous loss of their characteristic phenotype and function during culture in vitro9,12–14.
For clinical purposes Tregs are used to be expanded for up to 14 days in presence of IL-2 and magnetic beads 
coated with anti-CD3 and anti-CD28 antibodies (Ab)5–7,9,15. However, even in these established culture conditions 
and in the same laboratory, the fold increase of Treg number may vary between the expansions from several to 
nearly 50 times9,15. Hippen et al. reported in 3 experiments ≈3000 and ≈50 million-fold expansion of Tregs after 
14 and 55 days, respectively. Nevertheless, instead of beads they restimulated Tregs with anti-CD3 Ab loaded 
KT64/86 cell line16. KT64/86 cells were recently used for clinical Treg expansion10, however the risk of cancer cell 
implementation to the clinical protocol of Treg culture has to be always considered.
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An important and unsolved problem related to Treg expansion in vitro is a continuous decrease in frequency 
of FoxP3+ cells12,14. Even highly purified by fluorescence-activated cell-sorting (FACS) CD4+CD25HighCD127-/Low 
T cells (≈100% post-sort purity) present variable proportions of FoxP3+ cells (50–75%) after 2–3 weeks of 
expansion in vitro12,14. As FoxP3 downregulation results in loss of regulatory function of Tregs17, this is a serious 
problem for all Treg based clinical therapies. At some point rapamycin seemed to be the solution for this issue. 
However, recent studies confirm that the drug preferentially inhibits proliferation of conventional T cells that 
can contaminate Treg culture18, but does not prevent loss of FoxP3 expression in natural Tregs during the second 
week of expansion13,19. Noteworthy, 5-10-fold reduction in Treg proliferation in presence of rapamycin was also 
reported16.
It has been demonstrated that stable FoxP3 expression in natural Tregs depends on selective demethylation 
of Treg-specific demethylated region (TSDR) of FoxP3 gene20. Nevertheless, it was also reported that during 
expansion in vitro TSDRs undergo methylation even in natural Tregs. This phenomenon was accompanied by 
continuous decrease in FoxP3 expression, and suppressive activity of Tregs, as well as increasing production of 
proinflammatory cytokines12. Thus, in the context of clinical trials, an improvement of current Treg expansion 
protocols is required to prevent TSDR methylation, loss of FoxP3 expression and Treg function in vitro.
In the present paper, we describe how to preserve Treg phenotype and function during culture in vitro with-
out using chemical compounds affecting cell viability and safety of potential clinical therapy. We present how to 
efficiently expand stable and highly suppressive FoxP3High Tregs with unmethylated TSDRs by changing only a 
temperature of cell culture. Presented protocol makes the final result of Treg expansion more predictable, than it 
was reported before. Pure and stable Treg population after expansion can help to standardize Treg therapy, and 
thus make it safer and more efficient. The strategy can be also used for effective expansion of rare antigen-specific 
Treg clones that seem to be the most promising tool for therapy of autoimmune diseases. Finally, presented data 
shed new light on temperature- thought to be the fixed and not manipulable parameter in Treg culture, as well as 
help to better understand regulation of Treg responses.
Results
Temperature of 33 °C induces robust proliferation of Tregs. 14-day culture of Tregs at 33 °C resulted 
in 4.5-fold higher cell counts as compared with Tregs expanded at 37 °C (median fold increase 275.52 vs 1261.5, 
respectively, Mann–Whitney U test, MW, p = 1 × 10−3; Fig. 1A). Daily analysis of size and granularity of Tregs 
expanded at 37 and 33 °C showed that cells cultured at mild hypothermia were slightly bigger and more granular 
at each time-point, than Tregs expanded at standard culture temperature. However, the differences were not 
statistically significant (Fig. 1B). In addition, different proliferation dynamics for Tregs expanded at 33 and 37 °C 
were observed. During the first 4 days of the culture Tregs kept at 33 °C revealed lower proliferation rate than 
those at 37 °C. Nevertheless, after this period a significant acceleration in their proliferation has been observed 
and since day 7 Treg counts at 33 °C were higher, than at 37 °C. Intensive Treg proliferation at 33 °C was kept until 
the end of 14-day cultures, while an inverse trend was observed at 37 °C (Fig. 1C).
In 2/13 cultures at 37 °C Tregs proliferated significantly less extensively (fold increase 16.26 and 32), than 
it was observed at this temperature typically. No similar phenomenon was observed when cells from the same 
donors were expanded at 33 °C (fold increase 1446.1 and 1130, respectively). However, because of significant 
deviation, these 2 experiments were not included into statistical calculations.
Further reduction of culture temperature to 29 °C almost completely ceased Treg proliferation (average fold 
increase <3). While hyperthermia of 39 °C has less deleterious impact on Tregs and the cells passed significantly 
more rounds of divisions at these conditions than at 29 °C. However, fold expansion at 39 °C was significantly 
lower than at 37 and 33 °C (127.1 vs 730 and 1261.5, respectively).
All Treg cultures were characterized by high post-sort purity and no significant deviation in this parame-
ter was observed between the samples. On average after the isolation 98.9% (median, range 97–99.5%) of the 
cells presented CD3+CD4+CD25HighCD127−/Lowlin−doublet− Treg phenotype and median contamination with 
CD4+CD25−, CD4+CD127High and CD4+CD25−CD127High cells, all considered as CD4+ effector T cells (Teffs), 
was equal to 0.4%, while non-Th (CD4−) cells constituted 0.6% (median) of the sorted population.
Temperature of 33 °C enhances expression of FoxP3, CD25, CTLA-4, CD39 and Helios in Tregs 
and keeps Treg phenotype stable during culture in vitro. Tregs cultured at 33 °C were characterized 
by significantly higher frequency of FoxP3+ T cells on day 7 and 14 (MW, p = 0.01 and p = 8 × 10−5, respectively) 
of the expansion than those cultured at 37 °C (Fig. 2A,B). FoxP3 expression was also significantly more stable 
over time in cells expanded at 33 °C. There was a 13.2% (median) decrease in frequency of FoxP3+ cells between 
day 7 and 14 when Tregs were expanded at 37 °C, while only 2% (median) decrease was observed at 33 °C (MW, 
p = 1 × 10−4; Table 1). In addition, since day 7 an escalating trend towards higher intensity of FoxP3 production 
by FoxP3+ cells was observed at 33 °C and on day 14 FoxP3+ cells expanded at 33 °C produced on average ≈2 fold 
more FoxP3 than corresponding Tregs at 37 °C (MW, p = 0.02; Fig. 2C).
When expression of CD25 was analyzed, we found that nearly 100% of CD4+FoxP3+ Tregs expanded at 33 °C 
were simultaneously CD25High cells for entire duration of the culture, while frequency of CD25High cells within 
CD4+FoxP3+ population was significantly lower at 37 °C (MW, p = 2 × 10−4 on day 7 and 14; Fig. 1D,E). In addi-
tion, CD4+FoxP3+CD25High Tregs cultured at 33 °C produced significantly more CD25 than corresponding cells 
at 33 °C (MW, p = 0.01 on day 7and 14; Fig. 1F). Further analysis revealed that expression of CD25 was more 
stable in Tregs cultured at 33 °C than those at 37 °C (MW, p = 2 × 10−3; Table 1).
Analogously, frequency of Helios+ cells within CD4+FoxP3+ population was significantly higher at 33 °C 
(median = 93.2%) on day 14 than at 37 °C (median = 64.9%, MW, p = 0.03; Fig. 1G,H). When % of Helios+ cells 
on day 7 and 14 was compared, we found stable Helios expression only at 33 °C (Table 1, Fig. 1H). No differences 
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in intensity of Helios expression (MFI) in CD4+FoxP3+Helios+ cells were observed when Tregs expanded at 33 
and 37 °C were compared.
In addition, Tregs cultured at 33 °C comprised significantly more FoxP3High cells at day 7 (MW, p = 1 × 10−3, 
median = 86%) and 14 (MW, p = 2 × 10−5, median = 77.6%) than Tregs expanded at 37 °C (median, 72.3% and 
39.6%, respectively; Figs 2A and 3A). Noteworthy, significantly more CD4+FoxP3High cells had also phenotype 
of CD25High cells when expanded at 33 °C, as compared with the corresponding population at 37 °C at both con-
trol points (MW, day 7 p = 1 × 10−3, day 14 p = 2 × 10−3; Figure S1A). CD4+FoxP3HighD25High cells expanded at 
33 °C expressed also more CD25 than those cultured at 37 °C (MW, day 7 p = 0.01, day 14 p = 0.04; Figure S1B). 
Analogously to FoxP3+ cells, FoxP3High population was more stable at 33, than at 37 °C. Tregs expanded at 33 °C 
were characterized by significantly lower decrease in number of CD4+FoxP3High and CD4+FoxP3HighCD25High 
cells during culture in vitro, than those expanded at 37 °C (MW, p = 0.04 and p = 0.02, respectively; Table 1).
When other Treg associated markers were analysed, we found that nearly 100% (median ≥99%) of Tregs were 
positive for CD39 and CTLA-4 during entire culture in vitro regardless culture temperature. In addition, inten-
sity of CTLA-4 and CD39 expression was found to increase with time at both studied conditions (MW, day 7 vs 
day 14 at 37 and 33 °C p ≤ 0.05, Fig. 3B). However, Tregs expanded at 33 °C were characterized by significantly 
higher expression of CTLA-4 (MW, p = 0.01) and CD39 (MW, p = 8 × 10−3) on day 14, than cells cultured at 37 °C 
(Fig. 3B). In addition higher expression of CTLA-4 and CD39 corresponded with greater production of FoxP3 on 
day 14 (Spearman’s rank correlation, SRC; R = 0.75, p = 4 × 10−3 and R = 0.6,p = 0.03, respectively). Frequencies 
of Nrp-1+ Tregs at both studied culture conditions were comparable and low (on day 7 and 14 median <5%). 
These results are in accordance with study of Battaglia et al. who showed that CD4+Nrp1+ T cells in human 
peripheral blood are exceedingly rare and most of them do not express Treg markers CD25 and Foxp321. In 
Figure 1. Mild hypothermia of 33 °C stimulates Treg proliferation. (A) Fold increase of initial Treg number 
after 14-day expansion at 37 and 33 °C (gray and red symbols, respectively; n = 11). Statistical differences 
were calculated with Mann- Whitney U test and are presented as medians (min.-max.). *p < 0.05. (B) 14-day 
follow-up of size (FSC) and granularity (SSC) of Tregs cultured at 37 (black symbols) and 33 °C (red symbols; 
n = 4). Arrows point the days of cell stimulation with anti-CD3/CD28 beads. Median fluorescence intensity 
(MFI) of FSC and SSC is presented as value to power of 4 or 5 (e.g. 8E4 = 8 × 104).(C) 14-day follow-up of 
proliferation dynamics of CFSE stained Tregs cultured at 37 (black histograms) and 33 °C (red  histograms). 
Results of 1 of 4 representative experiments are shown for day 0 (1st CFSE staining), day 3, day 7 before and after 
2nd CFSE staining, day 10 and day 14. Blue and green histograms depict fluorescence of unstained and freshly 
stained cells, respectively.
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addition, no statistically significant differences were found for intensity of Nrp-1 expression by Nrp-1+ Tregs 
expanded at 33 and 37 °C (data not shown).
Unexpectedly, Tregs cultured at 33 and 37 °C did not differ in proportions of naive (Tn, 
CD4+FoxP3+CD45RA+CD62L+), central memory (Tcm, CD4+FoxP3+CD45RA-CD62L+) and effector memory 
(Tem, CD4+FoxP3+CD45RA-CD62L-) cells on day 7 and 14 of the expansion (Fig. 3C). In addition, after 14-day 
culture median/mean frequency of all CD45RA+ cells within CD4+FoxP3+ population at 37 °C and 33 °C was 
equal to 62.8/56.5% and 50.7/54.8%, respectively.
As hypothermia is associated with cold stress, we aimed to analyse expression of heat shock proteins (HSPs) 
−60, −70 and −90 that are molecular chaperones known to protect cells from cellular and environmental stress 
factors22. However, no differences in intracellular expression of HSP-60, −70 and −90 (Figure S2), as well as 
their gene transcription (Table S1) were found between Tregs expanded at 33 and 37 °C. No correlations between 
expression of HSPs and FoxP3 or other Treg related markers were found. However, in both studied culture 
Figure 2. Temperature of 33 °C enhances expression of FoxP3, CD25 and Helios in Tregs. (A) Representative 
dot plots depicting FoxP3 expression in Tregs cultured at 37 and 33 °C for 14 days. CD4+ Teffs derived from the 
same donor and expanded at 37 °C are shown as a control. FoxP3+ cells are gated and their frequency within 
CD4+ population is shown in the right upper corner of each dot plot. Red line divides FoxP3+ population 
into FoxP3High and FoxP3Low cells which proportions are depicted with red and blue font, respectively. (B) 
Frequency of FoxP3+ cells within CD4+ population on day 7 and 14 of Treg expansion at 37 and 33 °C (gray and 
red symbols, respectively; n = 11). (C) Intensity of FoxP3 expression (MFI) in CD4+FoxP3+ cells after 14-day 
expansion at 37 and 33 °C (gray and red symbols, respectively; n = 11). (D) Representative dot plots depicting 
CD25 expression in Tregs cultured at 37 and 33 °C for 14 days. CD4+ Teffs derived from the same donor and 
expanded at 37 °C are shown as a control. CD25High cells are gated and their frequency is shown in the right 
upper corner of each dot plot. (E) Frequency of CD25High cells within CD4+FoxP3+ population on day 7 and 14 
of Treg expansion at 37 and 33 °C (gray and red symbols, respectively; n = 11). (F) Intensity of CD25 expression 
(MFI) by CD4+FoxP3+CD25High cells after 7 and 14-day expansion at 37 and 33 °C (gray and red symbols, 
respectively; n = 11). (G) Representative dot plots depicting Helios expression in Tregs cultured at 37 and 33 °C 
for 14 days. CD4+ Teffs derived from the same donor and expanded at 37 °C are shown as a control. Helios+ 
cells are gated and their frequency is shown in the right upper corner of each dot plot. (H) Percentage of Helios+ 
cells within CD4+FoxP3+ population at day 7 and 14 of Treg expansion at 37 and 33 °C (gray and red symbols, 
respectively; n = 5). MFI is presented as value to power of 4 or 5 (e.g. 1E5 = 1 × 105). Statistical differences 
(B-C,E-F,H) were calculated with Mann- Whitney U test and are presented as medians (min.-max.). *p < 0.05.
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conditions we observed a significant increase in magnitude of HSP-60, −70 and −90 expression during culture 
in vitro as compared with day 0 (data for Tregs before their isolation form peripheral blood mononuclear cells, 
PBMC, Figure S2).
In contrast to cells expanded at 33 °C, Tregs cultured at 29 °C were found to lose their characteristic phenotype 
dramatically fast (Figure S3A). Between day 7 and 14 on average a 64% decrease in frequency of FoxP3+ cells 
was observed at 29 °C (median % of FoxP3+ cells on day 7 and 14 was 79.3% and 14.8%, respectively). On day 14 
32.5% and 76.7% (median) of FoxP3+ cells remained CD25High and Helios+, respectively at this condition.
Unlike 29 °C, temperature of 39 °C did not affect Treg phenotype significantly. After 14-day culture at 39 °C 
frequency of FoxP3+ cells was 79.8%, while CD25High cells constituted 83.4% and 74.3% of CD4+FoxP3+ and 
CD4+ populations, respectively (Figure S3B).
In 2/13 cultures where Treg proliferation was significantly decreased at 37 °C the cells were losing their charac-
teristic phenotype dramatically fast between day 7 and 14. In these cultures 3.3 and 6.2% of cells remained FoxP3+ 
on day 14 at 37 °C, while in parallel cultures at 33 °C frequencies of FoxP3+ cells were 90.8 and 92.8%, respectively. 
However, these results were excluded from general data analysis as significant deviation.
Expansion at 33 °C prevents TSDR methylation during culture in vitro. Tregs expanded at 33 °C 
were characterized by significantly higher frequency of cells with demethylated TSDR after culture in vitro, than 
those at 37 °C. The differences have been escalating with time and reached statistical significance on day 14 (MW, 
p = 0.03; Fig. 3D). Notably, TSDR demethylation was kept stable over time only in Tregs cultured at 33 °C (Fig. 
3D and Table 1).
When we analyzed expression of gens known to be involved in regulation of TSDR demethylation20,23 we 
found a trend towards enhanced transcription of RUNX1 (log2 fold change = 0.54, p = 7 × 10−3, q = 0.24) and 
TET2 (log2 fold change = 0.34, p = 0.1, q = 0.74) in Tregs expanded at 33 °C, while MBD2 and CBFB were 
expressed at the same levels at both studied temperatures (log2 fold change = −0.02, p = 0.9, q = 0.99 and log2 
fold change = 0.04, p = 0.81, q = 0.99, respectively; Fig. 4; Table S1).
Higher frequency of cells with demethylated TSDR within Tregs expanded at 33 °C did not result from 
lower contamination with non-Th cells. Post-expansion analysis with flow cytometry showed that at both cul-
ture temperatures CD56+, CD16+, CD19+ and CD14+ cells constituted on average ≤ 0.5%, while CD8+ lym-
phocytes ≤2.5% of total population and up to 100% of CD8+ cells were also positive for CD4. Presence of 
double-positive T cells in Treg cultures was also reported by other group working on clinical application of Tregs9. 
In addition, RNA-seq revealed comparable amounts of transcripts for CD8A, CD8B, CD14, NCAM1/CD56, 
MS4A1/CD20, and FCGR3A/CD16a (Table S1) in Tregs expanded at 37 and 33 °C.
Tregs expanded at 33 °C produce less IFN-γ but are not significantly more potent inhibitors of 
IFN-γ production by Teffs than Tregs at 37 °C. After 14-day culture 2.5% and 4.5% (median) of Tregs 
were IFN-γ+, when cultured at 33 and 37 °C, respectively (MW, p = 7 × 10−3; Figure S4A). The results were con-
cordant with RNA-seq data that revealed significantly lower abundance of IFNG transcript in Tregs at 33 °C, than 
at 37 °C (log2 fold change = −3.5, p = 5 × 10−5, q = 6 × 10−3; Table S1).
No statistically significant differences between Tregs expanded at 33 and 37 °C where found when we com-
pared their capability for suppression of IFN-γ production by Teffs. Nevertheless, a slight trend towards stronger 
suppression by Tregs expanded under hypothermic conditions was observed (Figure S4B).
Tregs cultured at 33 °C inhibit Teff proliferation more efficiently than Tregs expanded at 
37 °C. Tregs cultured at 33 °C were found to suppress proliferation of Teffs more efficiently than those 
expanded at 37 °C. The effect was more pronounced for lower Treg:Teff ratios: ½:1, ¼:1 and 1/8:1 (MW, p = 0.03, 
p = 0.03 and p = 0.02, respectively; Fig. 5).
Tregs expanded at 33 °C present remarkably anti-inflammatory phenotype. According to 
RNA-seq data analysis Tregs expanded at 33 and 37 °C significantly differed in expression of 238 genes (Table S1). 
Only 43 out of 238 genes which expression was significantly changed at 33 °C (p and q values < 0.05) were found 
Tregs expanded at 37 °C Tregs expanded at 33 °C Difference
median min → max median min → max p
Difference between day 
7 and 14 of the culture
% of FoxP3+ cells within CD4+ population −13.2 −26 → −3.3 −2 −8 → + 0.4 1 × 10−4*
% of FoxP3High cells within CD4+FoxP3+ population −22.3 −57.2 → −1.7 −13.2 −28.9 → + 1.4 0.04*
% of Helios+ cells within CD4+FoxP3+ population −8.7 −45.8 → −0.1  + 1.1  + 0.1 → + 15.9 7 × 10−3*
% of CD25High cells within CD4+FoxP3+ population −7.9 −20.7 → −0.2 − 0.55 −2.6 → + 0.2 2 × 10−3*
% of CD25High cells within CD4+FoxP3High population −3.2 −17.9 → + 1 −0.3 −0.9 → + 0.2 0.02*
% of cells with demethylated TSDR −24.5 −45.9 → −6.6 −5.5 −13.74 → + 0.37 0.05
Table 1. Stability of Treg phenotype at 37 and 33 °C. The table presents differences in Treg phenotype between 
day 7 and 14 of the culture for cells expanded at 37 and 33 °C. To calculate the differences, results for day 7 were 
subtracted from results for day 14 and thus “−” and “+” mean decrease and increase of analyzed value over 
time, respectively. The data are results of 11 independent experiments, with the exception for Helios expression 
and TSDR demethylation where n = 5. The differences were calculated with Mann-Whitney U test, *p < 0.05.
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to be upregulated in cells expanded at 33 °C, including 17 transcripts (namely CYP4F3, GRM4, GRM7, LRRIQ4, 
PCDHB8, PDLIM4, STEAP2, ADCYAP1R1, ACVRL1, ADORA1, ASTN1, PLCB4, KCNJ3, ZNF385B, NRG1, 
NEU4, KCNIP3) that were detectable only in Tregs cultured at this temperature. Those with the most remarkable 
increase (log2 fold change > 0.7) included: IKZF2 (Helios encoding gene), HMOX1, IQGAP2, CDKN2A, CREG2, 
CXCR1, EXOC6B, PELI2, E2F2, GPR55, HIPK2, HPGD, ITM2C, PHTF2, PCDH8, RBM3, RDH10, KIAA1671, 
RFX7, SAMD3, SEMA3G, SLC7A11, TRAK2 and UBL3 (Table S1 and Fig. 4).
At the same time 195 genes were significantly (p and q values < 0.05) downregulated at hypothermic con-
ditions and for 7 of them (CCL17, IL9, BFSP1, HTR3B, SPIB, IRX5 and WNT5A) no mRNA was detected at 
33 °C, while they were transcribed at 37 °C (Table S1). Besides, transcripts of other 945 genes (e.g. IL1B, IL17REL, 
CCL14) were not detectable in Tregs expanded at 33 °C but at 37 °C. Although those differences were not statis-
tically significant, they clearly show that temperature of 33 °C suppresses transcription of ≈1000 genes in Tregs, 
while their expression at 37 °C is promiscuous (Table S1).
In general, downregulated genes at 33 °C were associated with cell activation (e.g. HLA-DR, HLA-DQ, 
CD40LG/CD40L, NFKB2, TNFRSF4/OX40, CD69, ICAM1)24, Th-1 and Th-17 responses (e.g. IFNG, IL1A, 
TNFRSF25, TNFSF11/RANKL, IL17RB, THY1/CD90, KLRB1/CD161, NFKBIZ)25–28, Th-2 cell activation (e.g. 
IL13, IL9, GATA3-AS1, CCL17)29–31 and basically with proinflammatory response (e.g. CCL3/MIP-Iα, CCL4/
MIP-Iβ, CCL5/RANTES)32 underling anergic character of Tregs expanded at 33 °C (Fig. 4, Table S1).
To get insight into the biological context of differentially expressed genes in our dataset we made core analysis 
in Ingenuity Pathway Analysis (IPA) software. Disease and function mode resulted in the list of 155 phenomena 
Figure 3. Tregs expanded at 33 °C are more stable and express higher amounts of Treg associated markers, 
than the cells cultured at 37 °C despite the same proportions of naive and memory subsets. (A) Frequency of 
FoxP3High cells within CD4+FoxP3+ population on day 7 and 14 of Treg expansion at 37 and 33 °C (gray and red 
symbols, respectively; n = 11). (B) Intensity of CTLA-4 and CD39 expression (MFI) by CD4+FoxP3+CTLA-4+ 
and CD4+FoxP3+CD39+ cells, respectively after 7 and 14-day expansion at 37 and 33 °C (gray and red symbols, 
respectively; n = 7). MFI is presented as value to power of 4 (e.g. 1E4 = 1 × 104). (C) Proportions of naive (Tn), 
central memory (Tcm) and effector memory (Tem) cells within CD4+FoxP3+ population at 37 and 33 °C on day 
7 and 14 of the culture (n = 11). (D) Frequency of cells with demethylated FOXP3 TSDR on day 7 and 14 of Treg 
expansion at 37 and 33 °C (gray and red symbols, respectively; n = 5). CD4+ Teffs derived from the same donors 
(black symbols, n = 5) and expanded at 37 °C are shown as a control. The statistical differences (A–D) were 
calculated with Mann-Whitney U test and are presented as medians (min.-max.). *p < 0.05.
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that were inferred to be significantly more downregulated and/or inhibited (z-score ≤−2, p-score < 0.05) by Tregs 
cultured at 33 °C, than by those at 37 °C. Ten functions with the lowest activation z-score (the most potent inhibi-
tion) are listed in Table 2, and strongly correlate with anti-inflammatory profile of Tregs expanded at hypothermic 
Figure 4. Tregs expanded at 33 °C present remarkably anti-inflammatory Treg-specific phenotype. Expression 
of selected: Treg associated genes (Treg AG), transcription factors (TFs), FoxP3 expression controlling genes 
(FEC), genes encoding receptors associated with cell migration (Homing) and genes for multiple chemokines 
and cytokines (Chemokines and cytokines) in 14-day cultures of Tregs expanded at 33 °C (Tr33, n = 3) and 
37 °C (Tr37, n = 3) are shown. Results for CD4+ Teffs (Teffs, n = 3) derived from the same donors and expanded 
for 14 days at 37 °C are shown as a control. Relative FPKM values were used for generation of the heatmap.
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conditions. Regulator effects algorithm implemented in IPA showed the association between our dataset mole-
cules, the upstream regulators and downstream effects. The corresponding regulatory network with the highest 
consistency score is presented in Figure S5.
Discussion
Temperature of 37 °C has been established the optimal temperature for human and animal cell cultures for years. 
As it is considered a physiological temperature of human body, none controverted that Tregs should be expanded 
at 37 °C. Nevertheless, in the current paper we showed for the first time that optimal temperature for Treg culture 
Figure 5. Tregs expanded at 33 °C are more potent inhibitors of Teff proliferation than Tregs cultured at 37 °C. 
(A) % of inhibition of Teff proliferation by Tregs expanded at 37 and 33 °C (gray and red symbols, respectively; 
n = 5). Results for various Teff:Treg ratios are shown. C1 = control unstimulated Teffs cultured without Tregs, 
value corresponds to complete inhibition of Teff proliferation (100%). C2 = control stimulated Teffs cultured 
without Tregs, value corresponds to complete lack (0%) of inhibition of Teff proliferation. (B) Histograms from 
1 representative experiment are shown. Violet and blue histograms depict fluorescence of C1 and C2 controls, 
respectively. Inhibitory effect of Tregs expanded at 37 and 33 °C is reflected with black and red histograms, 
respectively.
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is lower than currently established standard. We demonstrated that mild hypothermia of 33 °C preserves Treg 
phenotype and function during culture in vitro and makes Treg expansion more predictable, consistent and effec-
tive, than it was reported before.
Multiple previous studies, including ours suggested that natural Tregs down-regulate FoxP3 expression after 
repetitive stimulation in vitro and convert into non-regulatory cells in time-dependent fashion4,12–14,16. Then, 
Hoffmann et al. also reported that high FoxP3 expression and immunosuppressive potential of Tregs can be kept 
for 2-3-weeks in vitro when CD4+CD25HighCD45RA+ Treg subset is selected for expansion. Despite CD45RA+ 
Tregs were found to rapidly convert into CD45RA− cells during the culture, they presented more stable Treg 
phenotype and function after expansion, than Tregs derived from CD45RA- or mixed CD45RA+ and CD45RA- 
populations. Therefore, it was suggested that only CD45RA+ expressing Tregs can give rise to stable and homog-
enous T cell lines after expansion in vitro12,33. Nevertheless, in our current study the sorted Treg populations each 
time comprised both CD45RA+ and CD45RA- cells. Despite this initial cell heterogeneity, only Tregs expanded 
at 33 °C remained stable, regardless presence or absence of CD45RA. Moreover, frequencies of CD45RA+ cells, 
as well as proportions of naive and memory subsets identified according to expression of CD45RA and CD62L7,34 
were comparable in both culture conditions after expansion. Thus, CD45RA does not seem to be vital for Treg 
function and stability. These observations are in accordance with our recently published study that showed that 
CD45RA− Tregs can express high levels of FoxP3, have demethylated TSDR and are crucial for graft tolerance35. 
All together these data call into question the previously accepted dogma and indicate that Treg phenotype and 
function in vitro and in vivo does not depend on CD45RA.
Soon after discovery of Tregs it was suggested that they lose immunosuppressive activity during proliferation36. 
However, in our study Tregs cultured at 33 °C exhibited more potent immunosuppressive potential and simul-
taneously proliferated 4.5-fold more efficiently, than Tregs at 37 °C. This high proliferative potential can at least 
partially result from increased expression of α-chain of high-affinity receptor of IL-2 (CD25/ILR2A) on Treg 
surface at 33 °C. Two functional IL-2 receptors (IL2R) were described, the dimeric low-affinity receptor com-
posed of CD122 (IL2RB) and CD132 (IL2RG) and trimeric high-affinity receptor consisting of CD122, CD132 
and CD2537. Upregulation of CD25 could increase proportion of high-affinity to low-affinity IL2Rs on Tregs at 
33 °C. IL-2 is a known mitogen of T cells and factor required for Treg survival and proliferation37. Therefore, 
enhanced production of CD25 and thus upregulation of high affinity IL2R on Tregs at 33 °C could result in higher 
IL-2 responsiveness and proliferation. In addition, it is known that due to presence of high-affinity IL2R Tregs 
consume large amounts of IL-2 and thus deprive other T cells of the cytokine37. This mechanism, at least partially, 
could be responsible for stronger suppression of Teff proliferation by Tregs expanded at 33 °C in our study.
During our 12-year experience with ex vivo expansion of human Tregs we found that Tregs of some patients 
do not proliferate in vitro. Generally, these cells remain FoxP3+ but in some cases, like in the present study, they 
began to lose FoxP3 expression dramatically fast after the first week of the culture. This Treg proliferation arrest 
is not strictly related to donor age, however it is more frequent when cells derive from older individuals. We 
observed it in 3/100 expansions of Tregs from diabetic children and in the present study in 2/13 cultures at 37 °C 
(cells from healthy adult donors). Our experience is not unique. Theil A. and her group also observed that Tregs 
from some adult donors (2/12 samples) present very low proliferation rate, thus no clinically optimal Treg dose 
can be obtained (Theil A., personal communication at meeting of Action to Focus and Accelerate Cell-based 
Tolerance-inducing Therapies, Galway 2016). Brunstein CG et al. have also reported recently that 2/13 clinical 
Treg expansions failed to achieve the target cell dose due to low Treg proliferation10. This phenomenon is a seri-
ous problem for clinical Treg therapy. However, decreasing culture temperature to 33 °C we could overcome this 




1 activation of cells 3.18 × 10−13 −4.643
2 development of mononuclear leukocytes 2.55 × 10
−13 −4.077
3 generation of cells 1.54 × 10−13 −4.03
4 activation of leukocytes 9.87 × 10−13 −4.027
5 differentiation of cells 3.56 × 10−16 −3.942
6 migration of cells 3.18 × 10−14 −3.919
7 size of body 1.29 × 10−6 −3.881
8 recruitment of leukocytes 2.3 × 10
−11 −3.87
9 development of lymphocytes 9.99 × 10
−13 −3.819
10 cell movement 1.79 × 10−15 −3.792
Table 2. Top ten functions and diseases predicted to be altered by Tregs expanded at 33 °C in comparison with 
cells cultured at 37 °C. The table shows the top 10 Ingenuity Pathway Analysis (IPA) functions and diseases 
affected by Tregs expanded at 33 °C based on differentially expressed genes in these cells as compared with Tregs 
cultured at 37 °C. aAlgorithm in IPA designed to reduce the chance that random data will produce significant 
prediction. It identifies functions with the strongest prediction for increase (positive z-score) or decrease 
(negative z-score). Values of p-score <0.05 and z- score ≤−2 or ≥2 are considered significant.
www.nature.com/scientificreports/
1 0SCIenTIFIC REPORTS | 7: 11915  | DOI:10.1038/s41598-017-10151-1
FoxP3 positive (>90%) and proliferated extensively, when they were kept at 33 °C. Thus, a single and simple 
change in culture conditions can be a solution for this problem.
Our RNA-seq data and TSDR methylation analyses suggest that mild hypothermia not only stimulates Treg 
proliferation, but also induces different transcriptional program and influences epigenetic modifications that 
together provide Treg stability. Recent studies suggested that TSDR demethylation results, at least partially, 
from action of runt-related transcription factor 1 (Runx1) and core-binding factor subunit β (Cbf-β) that shield 
TSDR from methylating enzymes. These molecules were also shown to be required for Foxp3 mRNA and protein 
expression in Tregs20,23. In addition, it was demonstrated that TSDR demethylation in Tregs is regulated by DNA 
demethylase Tet2 (tet methylcytosine dioxygenase 2) that acts in cooperation with Mbd2 (methyl-CpG-binding 
domain protein 2)20,38,39. When we analyzed transcription of genes encoding these proteins in our samples, we 
found a pronounced trend towards enhanced expression of RUNX1 and TET2 in Tregs expanded at 33 °C as 
compared with those cultured at 37 °C. No differences were found for CBFB and MBD2 mRNA levels. These data 
suggest that Runx1 and Tet2 dependent pathways can be involved in stable TSDR demethylation in Tregs at hypo-
thermic conditions. In addition, previous studies showed that FoxP3-Runx1 complex represses IL2 and IFNG 
genes, and at the same time activates IL2RA/CD25 expression40. These data are consistent with our observations. 
Tregs expanded at 33 °C were characterized by higher transcription of Runx1 and FoxP3, as well as expression of 
FoxP3 protein and thus contained significantly less mRNA of IFNG and presented higher surface expression of 
CD25, than those at 37 °C. In neither of Treg samples transcripts of IL2 were detected.
Another important issue associated with effective Treg function is their stability under inflammatory condi-
tions. It was reported that Helios (IKAROS family zinc finger 2; IKZF2) renders Tregs anergic and suppressive 
even during intense inflammatory response. At the same time, Helios-deficient Tregs were found to be character-
ized by reduced expression of FoxP3, diminished lineage stability and secretion of proinflammatory cytokines. 
Recently it was even suggested that deletion of Helios promotes Treg conversion into Teffs41. In our study, only 
Tregs expanded at 33 °C were found to keep Helios expression at the same level for the entire culture duration, 
while its time dependent decrease was observed in Tregs at 37 °C. Stability of Tregs expanded at 33 °C was also 
confirmed by TSDR demethylation analysis. Only Tregs cultured at hypothermic conditions kept their TSDR 
demethylated throughout the culture in vitro and were significantly more potent inhibitors of Teff proliferation.
All these observations shed new light on impact of temperature on immune system, the issue that was thought 
to be completely explored. Fever and associated changes in immune response have been extensively studied many 
years ago42 and it seemed that the knowledge in this field was complete. However, our study provides fresh insight 
into biological sense of temperature changes. Fever is one of the most common symptoms of infection and signal 
for immune system activation. Bearing in mind that Tregs suppress immune responses and participate in their 
termination43, we should expect that fever deteriorates Treg function. However, once pathogen is eradicated, 
normothermia regained, Tregs should activate to prevent prolonged and potentially harmful immune response. 
Bearing in mind these interrelationships, increased Treg activity, stability and proliferation at lower temperature 
of 33 °C is not surprising. For effective immune defense Tregs need to be inhibited as long as pathogen is pres-
ent and fever is established. Thus, high temperatures should be expected to suppress and low temperatures to 
stimulate Treg proliferation and/or function. Our observations confirm this hypothesis. Only Tregs expanded 
at mild hypothermia were characterized by high and stable expression of FoxP3, Helios and CD25, as well as 
robust proliferation. In addition, 13/13 of Treg samples expanded at 33 °C vs 1/13 at 37 °C contained >59% of 
FoxP3High cells within FoxP3+ pool after 14-day expansion, while the amount of FoxP3 protein in Tregs correlates 
with their suppressor function44,45. Besides, Tregs cultured at 33 °C presented profound anti-inflammatory profile 
and no transcripts of IL1B, IL17REL, CCL17 and IL9 were detected in these cells, in contrary to Tregs at 37 °C. 
Transcription of several other genes involved in immune cell activation such as IL1A/IL1α, CD40LG/CD40L, 
TNFRSF4/OX40, NFKB2, IFNG, TNFRSF25, TNFSF10/TRAIL, TNFSF11/RANKL, CCL3, CCL4, CCL5, IL17RB 
and IL13 was significantly downregulated at 33 °C as compared with the cells cultured at 37 °C. Concomitantly, 
mild hypothermia enhanced Treg expression of HMOX1, a gene encoding heme oxygenase 1 (HMOX1). It was 
reported previously that HMOX1 expression is induced by FoxP3 and is critical in FoxP3-mediated immune 
suppression. Choi et al. demonstrated that Tregs became unable to suppress Teff proliferation after blockage 
of HMOX146. Subsequently, Brusko et al. proposed that Treg suppressive activity (inhibition of proinflamma-
tory cytokine production by Teffs and Teff proliferation) depends on production of carbon monoxide (CO) via 
HMOX1 in activated Tregs47. Moreover, studies in vivo showed that induction of HMOX1 prolongs graft survival, 
while inhibition worsens the outcome of allo- and xenotransplantation. This effect was dependent on direct and 
indirect actions of HMOX1 that included nonspecific cytoprotection from oxidative damage, vasodilation, anti-
platelet aggregation effect and inhibition of host inflammatory responses mediated by neutrophils, macrophages 
and lymphocytes47,48. Moreover, HMOX1 expression in donor and recipient tissues was shown to promote activa-
tion induced cell death of allorective lymphocytes after allograft transplantation49, while T cells transfected with 
HMOX1 were found to became resistant to Fas-mediated apoptosis50, suggesting that HMOX1 is important for 
both Treg function and survival. HMOX1 was also found to ameliorate various T cell mediated diseases due to its 
wide range of anti-inflammatory and immune regulatory mechanisms of action51–54. Inter alia, enhanced expres-
sion of HMOX1 in animal models of inflammatory bowel disease (IBD) and asthma was observed to attenuate 
symptoms of the diseases by inhibition of Th17 responses51. Moreover, Freitas et al. revealed that secreted metab-
olites of HMOX1 decreased leukocyte rolling, adhesion and neutrophil migration to the site of inflammation54. 
Thus, hypothermia induced upregulation of HMOX1 in Tregs can have a broad beneficial impact on immune 
tolerance induction after administration of these cells to patients.
In addition, Tregs expanded at 33 °C were characterized by higher expression of CTLA-4 and CD39 at the end 
of the culture. These two molecules contribute to Treg immunoregulatory function and play an important role 
in suppression of T cell activation and proliferation1,55. CTLA-4 is known to induce expression of indoleamine 
2,3-dioxygenase (IDO) in dendritic cells (DCs) that suppresses T cell proliferation via depletion of tryptophan 
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and accumulation of kynurenine56. While CD39 is an ectoenzyme involved in generation of pericellular aden-
osine that suppresses T cell function. Adenosine was also found to enhance generation of induced Tregs by 
inhibition of IL- 6 expression and promotion of TGFβ secretion1,55. Moreover, both CTLA-4 and CD39 favour 
generation of tolerogenic DCs1,55,57 that is of great importance for attenuation of deleterious immune response 
in vivo. All together these data show that hypothermia can have a broad impact on Treg activity and intercellular 
interactions. This way our study contributes to better understanding of beneficial effects of cryotherapy and reg-
ulation of the immune activation in general.
Prolonged hypothermia is associated with cold stress, therefore in the current study we measured intracellular 
expression and gene transcription of HSPs, phylogenetically conserved proteins known to protect the cells from 
cellular and environmental stress22. We hypothesized that hypothermia enhances expression of these molecules 
and that HSPs are responsible for preservation of Treg stability in vitro. Our theory was supported by previous 
studies of Vercoulen et al. and Zanin-Zhorov et al. who found that HSPs, notably HSP-60, can contribute to 
an increase in Treg number and function23,58,59. However, unexpectedly we found no alterations in intracellular 
expression of HSP-60, −70 and −90, as well as their gene transcription in Tregs expanded at 33 °C as compared 
with the cells at 37 °C. The only change in HSP expression in Tregs was observed when the cells at day 0 were 
compared with those expanded in vitro. However, the difference was the same for Tregs cultured at 33 and 37 °C. 
These data suggest that Treg transfer from peripheral blood to the artificial environment of the culture in vitro was 
a substantial stress that enhanced HSP expression, but mild hypothermia did not trigger this change. Thus, HSPs 
are not the crucial regulators of Treg response to temperature decrease.
In our study Tregs remained stable during culture in vitro at 33 °C, but the beneficial effect of hypother-
mia was kept also after transfer to 37 °C. All functional tests in our study were performed at 37 °C, as this is a 
physiological temperature of human body and ex vivo expanded Tregs are expected to function at this temper-
ature in vivo. In these tests Tregs previously expanded at 33 °C revealed higher suppressive potential at 37 °C, 
than those cultured at this temperature since the beginning. Undoubtedly, full verification if Tregs expanded 
at 33 °C have better therapeutic effect in vivo requires further studies, but the presented data shed new light on 
regulation of Treg function. We may expect that activation status of Tregs expanded ex vivo will be altered after 
transfer to human body. However, Tregs expanded at 33 °C will start their function in vivo with highly demeth-
ylated TSDRs, increased FoxP3 expression, greater suppressive and proliferative potential, thus it is likely that 
they will exert better therapeutic effect. Application of hypothermia for Treg culture can be compared to trivial 
storage of food in fridge. Refrigeration, does not modify the structure of food, but enables longer storage of 
fresh products that do not compromise human health. In the same way delivery of fresh, stable and functional 
Tregs expanded at hypothermic conditions can be crucial for safety and effectiveness of Treg based therapies. 
Therefore, we have already started Treg production for clinical applications at 33 °C in the current clinical trials 
(TregVAC2.0EudraCT:2014-004319-35 and TregSM EudraCT: 2014-004320-22). Our preliminary results con-
firm safety and efficacy of this method of Tregs expansion.
In summary in the present study we showed for the first time that optimal temperature for Treg culture in vitro 
is lower than standard temperature of 37 °C. We demonstrated that mild hypothermia of 33 °C preserves Treg 
phenotype and function during culture in vitro and makes Treg expansion more predictable, consistent and effec-
tive, than it was reported before. Tregs expanded at 33 °C were found to be more potent inhibitors of Teff prolifer-
ation. Despite higher expansion rate they were characterized by more quiescent phenotype and lower production 
of proinflammatory cytokines, as compared with Tregs expanded at 37 °C. Higher Treg stability, effectiveness and 
proliferation at 33 °C makes this temperature optimal for ex vivo expansion of Tregs when their clinical applica-
tion is planned and can be considered by teams who work on Treg based therapies.
Methods
Blood donors. Buffy coats were obtained from the Regional Centre for Blood Donation and Treatment 
in Gdańsk. All blood donors (n = 13) gave informed consent and all experimental protocols were approved 
by Independent Bioethics Commission for Research of the Medical University of Gdańsk (agreement no. 
NKEBN/353/2011). The study was conducted in accordance with guidelines of the Commission and Declaration 
of Helsinki.
Treg and CD4+Teff isolation. Tregs and CD4+ Teffs were freshly isolated from buffy coats obtained from 
13 volunteer blood donors according to our previously described protocol. Briefly, on the day of blood donation 
peripheral blood mononuclear cells (PBMC) were isolated from buffy coats by Ficoll/Uropoline gradient centrif-
ugation and subjected to negative immunomagnetic selection (StemCell Technologies, Canada). Subsequently, 
CD4+ T cells were stained with monoclonal antibodies (mAb) specific for the following antigens: CD3, CD4, 
CD25, CD127, CD8, CD19, CD16 and CD14. The last 4 mAbs were conjugated with the same fluorochrome 
in aim to cut-off in one step cytotoxic T cells (Tc), B cells, natural killer (NK) cells and monocytes, respectively, 
that could potentially contaminate isolated CD4+ population. These cells were defined all together in sorting 
algorithm as lineage. Then, cells were sorted with FACS sorter Influx (BD Biosciences, USA) into the follow-
ing phenotype of Tregs: CD3+CD4+CD25HighCD127−/Lowlin−doublet- and Teffs: CD3+CD4+CD25-CD127Highlin
−doublet- as it was reported before4–7,14,60.
Cell expansion. After sorting Tregs were equally divided into 2 separate cultures marked as Tregs37 and 
Tregs33 and were expanded at 37 °C and 33 °C, respectively. In parallel sorted CD4+ Teffs were cultured at 
37 °C, as they were used in further experiments and served as a control for Treg phenotype analysis. Besides 
difference in the culture temperature, other parameters of the expansion were the same for all cells. All Tregs 
and Teffs were expanded in penicillin (100 U/ml) and streptomycin (100 mg/ml) containing SCGM medium 
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(CellGro, CellGenix, Germany) supplemented with 10% heat inactivated human AB serum, IL-2 (2 × 103 U/mL, 
Aldesleukin, Chiron, USA) and magnetic beads coated with anti-CD3 and anti-CD28 antibodies (Invitrogen, 
USA) in a 1:0.6 cell:bead ratio. Beads were added to the cultures on day 0 and 7.
In the selected experiments size and granularity of Tregs37 and Tregs33 were analyzed daily with flow cytom-
etry on basis of forward (FSC) and side scatter (SSC) parameters.
In aim to analyze dynamics of Treg proliferation in studied temperatures samples of Tregs37 and Tregs33 were 
stained with 5 μM of 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE; Vybrant® CFDA SE Cell Tracer 
Kit, Life Technologies, USA) for 15 min. at 37 °C on day 0 and CFSE fluorescence was measured daily. As com-
plete loss of CFSE fluorescence was observed after 7 days due to intensive cell proliferation and consequent dye 
dilution, the cells were stained again after this period and restimulated. Strong polyclonal stimulation of Treg pro-
liferation at 37 and 33 °C induced division cycle synchronization within each culture. Therefore, as it was reported 
before61, a progressive shift of a single peak of CFSE fluorescence was observed over time for each studied culture 
and their mean fluorescence intensities were analyzed to assess proliferation dynamics.
In 2 control experiments Tregs were cultured also at 29 °C and in a single experiment at 39 °C in aim to check 
an impact of significant change in standard culture temperature on Treg phenotype and proliferative capabilities.
Each time Tregs were cultured for 14 days and then harvested and counted after bead removal. The fold 
increase in cell number was calculated as final cell count on day 14 divided per initial cell number on day 0.
Phenotype check. Each 7th and 14th day of the expansion samples of Tregs37, Tregs33 and Teffs were labe-
led with Abs against the following antigens (Ag): CD4, CD25, CD127, CD45RA (BD Biosciences, USA), CD62L 
(Life Technologies, USA), Nrp-1 (BioLegend, USA), HSP-60, HSP-70, HSP-90 (Abcam, UK), CD39, CTLA-4, 
Helios and FoxP3 using Foxp3 Staining Buffer Set (eBioscience, USA) and analyzed with flow cytometry (Canto 
II, BD Biosciences, USA). As it was reported before7,34 Tregs were assigned to naive (Tn), central memory (Tcm) 
and effector memory (Tem) populations according to the following phenotypes: CD4+FoxP3+CD45RA+CD62L+, 
CD4+FoxP3+CD45RA-CD62L+ and CD4+FoxP3+CD45RA-CD62L−, respectively.
IFN-γ inhibition assay and measurement of IFN-γ production by Tregs. At 13th day of the expan-
sion samples of Teffs were stained with CFSE (5 μM) for 15 min. at 37 °C and mixed with unstained Tregs37 or 
Tregs33 in the following proportions: 1:1, 1:1/2, 1:1/4 and 1:1/8. Cells were cocultured for the next 24 h at 37 °C (as it 
is considered a physiological temperature of human body) in SCGM medium supplemented with 10% heat inac-
tivated human AB serum, IL-2 (100 U/ml), monensin, a protein transport inhibitor (GolgiStop, BD Biosciences; 
2 μl/1000 μl of medium) and beads coated with anti-CD3 and anti-CD28 antibodies in a 1:1 Teff:bead ratio. In 
these experiments Teffs were stained with CFSE in aim to distinguish them from Tregs in cocultures during anal-
ysis of IFN-γ production. CFSE stained Teffs cultured alone in presence or absence of beads were used as controls. 
In addition, IFN-γ production by bead stimulated Tregs37 and Tregs33 cultured alone was also measured. After 
24 h cells were harvested, labeled with anti-CD4 and anti-IFN-γ mAbs and analyzed with flow cytometer (Canto 
II, BD Biosciences, USA).
Data were analyzed as % of inhibition of IFN-γ production by Teffs. Results for all tested Teff:Treg proportions 
were analyzed in relation to two controls-unstimulated Teffs (C1) and bead-stimulated Teffs (C2), both cultured 
without Tregs. All data were converted in the same way, thus % of inhibition of IFN-γ production for unstim-
ulated control Teffs was always equal to 100% and reflected lack of Teff activation and complete suppression of 
IFN-γ synthesis, while results for control stimulated Teffs were always equal to 0% and signified lack of inhibition 
of IFN-γ synthesis. Consequently, the more effective in suppression of IFN-γ production were Tregs, the higher 
% of inhibition of IFN-γ production was observed.
Proliferation inhibition assay. At day 7 of the expansion a proliferation inhibition assay was performed. 
Teffs were stained with 2 μM of Violet Proliferation Dye 450 (VPD-450; BD Horizon, USA) for 15 min. at 37 °C 
and mixed with unstained Tregs37 and Tregs33 in the following Teff:Treg proportions: 1:2, 1:1, 1:1/2, 1:1/4, and 
1:1/8. Cells were cocultured for the next 4 days at 37 °C in SCGM medium supplemented with 10% heat inactivated 
human AB serum and expanding beads in a 1:1 Teff:bead ratio. VPD-450 stained Teffs cultured alone in presence 
or absence of beads were used as controls. Just before the read-out, cells were labeled with 7-amino-actinomycin 
D (7-AAD, BD Pharmingen, USA) a compound that binds to DNA of nonviable cells in aim to exclude dead cells 
and then subjected to flow cytometry (Canto II, BD Biosciences, USA).
Data were analyzed as % of inhibition of Teff proliferation. Results for all tested Teff:Treg proportions were 
analyzed in relation to two controls-unstimulated Teffs (C1) and bead-stimulated Teffs (C2), both cultured with-
out Tregs. All data were converted in the same way, thus % of inhibition of Teff proliferation for unstimulated 
control Teffs was always equal to 100% and reflected lack of Teff activation and complete suppression of their 
proliferation, while results for control stimulated Teffs were always equal to 0% and signified lack of inhibition 
of proliferation. Consequently, the more effective in suppression of Teff proliferation were Tregs, the higher % of 
inhibition of Teff proliferation was observed.
DNA methylation of the Treg-Specific Demethylated Region (TSDR). Genomic DNA from 
7-day and 14-day cultures of Teffs, Tregs37 and Tregs33 was extracted with the QIAamp DNA blood mini kit 
(Qiagen, Hilden, Germany). A minimum of 60 ng bisulfite-treated (EpiTect; Qiagen) genomic DNA was used 
in a real-time PCR to quantify the Foxp3 Treg-specific demethylated region (TSDR). Real-time PCR was per-
formed in a final reaction volume of 20 µl containing 10 µl FastStart universal probe master (Roche Diagnostics, 
Mannheim, Germany), 50 ng/µl lamda DNA (New England Biolabs, Frankfurt, Germany), 5 pmol/µl methyla-
tion or non-methylation-specific probe, 30 pmol/µl methylation or non-methylation-specific primers and 60 ng 
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bisulfite-treated DNA or a respective amount of plasmid standard. The samples were analyzed in triplicates on a 
ABI 7500 cycler and reported as % of T cells with demethylated TSDR region. Treg samples with extremely low 
FoxP3 expression (2/13 cultures at 37 °C) were not subjected to these analyses as they were considered a signifi-
cant deviation.
Transcriptome analysis using massively parallel sequencing (RNA-seq). RNA-seq was performed 
for 14-day cultures of Tregs37 and Tregs33. CD4+ Teffs from the same donors and expanded at 37 °C were ana-
lyzed as controls. Total RNA was isolated using RNeasy Mini Kit (Qiagen, Hilden, Germany), followed by qual-
ity and quantity assessment using 2100 Bioanalyzer (Agilent, Santa Clara, USA). RNA with a RNA Integrity 
Number (RIN) of 7.0 or above was used for sequencing library preparation. SureSelect Strand Specific mRNA 
library kit (Agilent, Santa Clara, USA) starting with two rounds of polyA selection was used followed by the 
standard procedure. The cDNA libraries were quantitated using qPCR in a Roche LightCycler 480 with the 
Kapa Library Quantification Kit for Illumina (Kapa Biosystemks, Woburn, USA) prior to cluster generation. 
mRNA-sequencing was performed on the Illumina HiSeq 2500 using the Rapid Run v2 sequencing chemistry 
and flow cells as described by the manufacturer (Illumina Inc., San Diego, USA). Cluster generation was per-
formed according to the manufacturers recommendations for onboard clustering. Paired end 50 bp sequencing 
runs were completed and the data were converted to the FASTQ Sanger format using FASTQ Groomer. TopHat 
was used to align RNA-Seq reads to hg19 reference genome using the short-read aligner Bowtie62. SAM files 
were directly used as input in Cuffdiff 2.2.163 implemented in Galaxy 2.2.1.364 to look for significant changes 
in transcript expression in Tregs37 and Tregs33 with three replicates for each condition. We used quartile nor-
malization method for the libraries, per-condition dispersion method for replicates and biased correction using 
canonical hg19 as reference. Additionally, differentially expressed genes were grouped in functional pathways 
with Ingenuity Pathway Analysis software (IPA Fall Release 2016, Redwood City, USA). Fisher’s exact test was 
implemented to measure the likelihood that the association between the differentially expressed genes and a given 
pathway is not due to random chance.
Statistical analysis. Flow cytometry data were calculated with Statistica 12.0 software (Statsoft, Poland) 
and values at p < 0.05 were deemed significant. As data were not normally distributed, Mann-Whitney U test and 
Spearman’s rank correlation were used. Differences in gene expression calculated in Cuffdiff software were con-
sidered statistically significant when uncorrected p-value and FDR-adjusted q-value were both < 0.05. The Core 
Analysis in Ingenuity Pathway Analysis allowed to identify causes and effects related to differentially expressed 
genes in our dataset. Visualization of RNA-seq data as heat map was performed with ClustVis tool freely available 
at http://biit.cs.ut.ee/clustvis/#mathematics. Flow cytometry data were analyzed with BD FACS Diva v8.01 and 
FlowJo v7.6 softwares.
Data Availability. Both next generation sequencing (NGS) raw and processed matrices are available in 
ArrayExpress database (http://www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-5322.
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